From the “X-Files” of Dr. Patricia M. Jordan, DVM comes this incredible snippet dateline 2009:

ST-246 Used to Treat Complications From Exposure to Recombinant Vaccinia Virus

Tue Sep 15, 2009 8:31am EDT;h=v8/38a9/0/0/%2a/v;44306;0-0;0;38919074;1627-170/40;0/0/0;;~okv=;seg1=10018;seg1=10067;type=featured_broker;sz=170×40;articleID=US115138 15-Sep-2009 GNW20090915;~aopt=2/1/bf/1;~sscs=%3f

NEW YORK, Sept. 15, 2009 (GLOBE NEWSWIRE) — SIGA Technologies Inc.

(Nasdaq:SIGA) announced that its smallpox antiviral drug, ST-246, has been used

to treat a Pennsylvania patient suffering from complications due to exposure to

a live vaccinia-vectored rabies vaccine. Following consultation with the

Pennsylvania Health Department, the Centers for Disease Control and Prevention,

and the Food and Drug Administration, an eIND (Emergency Investigational New

Drug) was approved to permit the use of ST-246, an investigational drug, in the

patient. After a single 14-day course of oral ST-246 therapy (2 capsules once

per day), together with vaccinia immunoglobulin (VIG), the infection was

resolved and the patient was discharged from the hospital.


In an effort to control wildlife rabies, bait sachets containing recombinant

vaccinia virus expressing rabies antigens are distributed in the rural areas of

the Eastern United States. The intent is to allow wildlife to self-vaccinate by

ingesting the vaccine-laden bait sachets. They do not pose an immediate health

risk to humans or pets, but should not be handled. In this particular case,

through an unfortunate set of circumstances, an individual acquired an infection

through direct contact with a bait sachet.


“This case illustrates the potential of ST-246 to treat orthopoxvirus-related

infections, to treat vaccine complications and to diminish the threat posed by

poxvirus bioweapons,” said Dr. Eric A. Rose, SIGA’s Chief Executive Officer.


About SIGA Technologies, Inc.


SIGA Technologies is applying viral and bacterial genomics and sophisticated

computational modeling in the design and development of novel products for the

prevention and treatment of serious infectious diseases, with an emphasis on

products for biological warfare defense. SIGA believes that it is a leader in

the development of pharmaceutical agents to fight potential bio-warfare

pathogens. SIGA has antiviral programs targeting smallpox and other Category A

pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito,

Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses

(Ebola and Marburg). For more information about SIGA, please visit SIGA’s web

site at


The SIGA Technologies, Inc. logo is available at


Forward-looking Statements


This press release contains or implies certain “forward-looking statements”

within the meaning of the Private Securities Litigation Reform Act of 1995, as

amended, including statements regarding the efficacy of potential products, the

timelines for bringing such products to market and the continued development and

possible eventual approval of such products. Forward-looking statements are

based on management’s estimates, assumptions and projections, and are subject to

uncertainties, many of which are beyond SIGA’s control. Actual results may

differ materially from those anticipated in any forward-looking statement.

Factors that may cause such differences include the risks that (i) potential

products that appear promising to SIGA or its collaborators cannot be shown to

be efficacious or safe in subsequent pre-clinical or clinical trials, (ii) SIGA

or its collaborators will not obtain appropriate or necessary governmental

approvals to market these or other potential products, (iii) SIGA may not be

able to obtain anticipated funding for its development projects or other needed

funding, (iv) SIGA may not be able to secure funding from anticipated government

contracts and grants, (v) SIGA may not be able to secure or enforce sufficient

legal rights in its products, including sufficient patent protection for its

products, (vi) regulatory approval for SIGA’s products may require further or

additional testing that will delay or prevent approval, (vii) the Biomedical

Advanced Research & Development Authority may not complete the procurement set

forth in its solicitation for the acquisition of a smallpox antiviral for the

strategic national stockpile, or may complete it on different terms; (viii)

SIGA’s proposed drug candidate for responding to any governmental solicitation

for purchase may not meet the requirements of the solicitation; (ix) the

volatile and competitive nature of the biotechnology industry may hamper SIGA’s

efforts, (x) changes in domestic and foreign economic and market conditions may

adversely affect SIGA’s ability to advance its research or its products, and

(xi) changing federal, state and foreign regulation on SIGA’s businesses may

adversely affect SIGA’s ability to advance its research or its products. More

detailed information about SIGA and risk factors that may affect the realization

of forward-looking statements, including the forward-looking statements in this

press release, is set forth in SIGA’s filings with the Securities and Exchange

Commission, including SIGA’s Annual Report on Form 10-K for the fiscal year

ended December 31, 2008, and in other documents that SIGA has filed with the

Commission. SIGA urges investors and security holders to read those documents

free of charge at the Commission’s Web site at Interested

parties may also obtain those documents free of charge from SIGA.

Forward-looking statements speak only as to the date they are made, and, except

for any obligation under the U.S. federal securities laws, SIGA undertakes no

obligation to publicly update any forward-looking statement as a result of new

information, future events or otherwise.

CONTACT:  KCSA Strategic Communications

Marybeth Csaby


Todd Fromer



Now, take a look at this from Homeland Security’s Website:

HHS awards SIGA Technologies smallpox contract worth up to $2.8 billion

Published 17 May 2011

New York-based SIGA Technologies has signed a 5-year, $433 million contract with the U.S. Department of Health and Human Services (HHS) to deliver two million courses of the company’s smallpox antiviral, ST-246, to the Strategic National Stockpile; the contract includes options that would raise the contract’s total value to approximately $2.8 billion if these options are fully exercised

New York-based SIGA Technologies, Inc. (NASDAQ: SIGA), a specialist in the development of pharmaceutical agents to fight biowarfare pathogens, said it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) to deliver two million courses of its smallpox antiviral, ST-246, to the Strategic National Stockpile. The 5-year base contract award is worth $433 million and includes options that would raise the contract’s total value to approximately $2.8 billion, if these options are fully exercised. Contract options include the delivery of up to twelve million additional courses of ST-246.

“BARDA’s selection of ST-246 for the Strategic National Stockpile underscores the U.S. government’s commitment to Project BioShield and the procurement of medical countermeasures to address the threat of a smallpox attack,” stated Dr. Eric A. Rose, SIGA’s chairman and CEO.

The contract award confirms SIGA’s status as a leader in the biodefense industry and highlights our abilities in drug discovery, development and commercialization. Within just five years of the first non-human primate trial for ST-246, we are getting ready to deliver the world’s first completely new small-molecule drug to address a major bioterrorism threat and one of the most lethal diseases in history. We value our new role as a provider of biodefense countermeasures to the U.S. government, which is the culmination of years of successful research and development collaborations with the U.S. government that have enabled us to take this drug to the commercial stage. We believe this keystone contract is a historic event for the biodefense industry and will be the first of many commercial successes for ST-246 here and around the world.

Under the contract, SIGA will deliver 1.7 million courses of ST-246. Additionally, SIGA will contribute 300,000 courses manufactured using federal funds provided by HHS under prior development contracts. In addition to the option to purchase up to an additional twelve million courses, the contract will also permit SIGA to continue its work on pediatric and geriatric versions of the drug as well as use of ST-246 for smallpox prophylaxis. Dr. Rose added, “We believe that the funding to extend ST-246 to these vulnerable populations is critical to the future success of the U.S. government’s smallpox biodefense efforts. There are approximately 64 million children in the United States (through age 15), none of whom is currently vaccinated against this disease.”


NEVER FEAR, Folks.  You can invest today in SIGA Technologies and literally “make a killing” in the stock market!!   You may also get your own personal stockpile of the wonder-drug ST-246 right away!!!  Just read this, (but as you do, keep in mind BARDA is a division of the “military-industrialist-complex and ZIONIST MOSSAD ENCLAVE DARPA):

Fighting Bio Terrorism with SIGA Technologies

Posted by Dave Goodboy on Jun 28, 2011 | View Comments

The United States has been on high alert for additional terrorist attacks since the attack on September11, 2001. Security has been ramped up everywhere in an effort to prevent another destructive event. One of the more insidious weapons used in warfare and potentially by stateless terrorists is biological. Biological weapons are among the most feared as they are silent and highly effective killers.

Fortunately, there are effective countermeasures against biological weapons.  In the United States, a division of the Office of the Assistant Secretary of Preparedness and Response known as the Biomedical Advanced Research and Development Authority or BARDA handles the procurement and advanced development of medical countermeasures for chemical, biological, radiological, and nuclear agents, as well as the advanced development and procurement of medical countermeasures for pandemic influenza and other emerging infectious diseases. This governmental agency stockpiles pharmaceutical products to be used in widespread medical emergencies like biological attacks. As you can imagine obtaining a contract from BARDA is a highly lucrative score for a company.

Our focus stock today, SIGA Technologies (Nasdaq: SIGA) is one such pharmaceutical company with a contract from BARDA. The contract is for 1.7 million courses of SIGA’s groundbreaking drug, ST-246, an oral therapeutic agent active against orthopoxviruses including smallpox. It is the only drug from any source ever to have demonstrated efficacy in non-human primate models of orthopox virus disease, which was a requirement of the request for proposal that resulted in the current contract. ST-246 will be the first entirely new small-molecule drug delivered to the Strategic National Stockpile under Project Bioshield. Smallpox, even though no longer present naturally in the environment, is considered a formidable bioterrorism threat, and there is currently no FDA-approved treatment for symptomatic individuals.

The contract was modified to just 1.7 million courses from the original option of 12 million.  It does not preclude BARDA from purchasing additional courses, however. Being that SIGA is the only company that produces this drug, it’s possible that the modified contract could work in SIGA’s favor. Being that its no longer optioned in the contract, should BARDA need to purchase additional product, price increases may now be possible.  I am not an expert in Government Pharma purchases but it makes sense on the surface.

Technically, shares have fallen sharply off their recent highs and are basing around the $10.50 per share range. $12.40 is significant resistance as the 200 day moving average for any up moves. Price is jumping higher on the contract news. A close eye should be kept on the $12.40 area!
Read more:


Let’s make sure EVERYBODY understands the clear facts here.  We the People are being asked to believe that TERRORISTS connected to the dead Bin Laden have somehow miraculously acquired recombinant “ORTHOPOX VIRUSES” – a recombinant “mutant” virus  or “chimera” virus and that deployment of this killer has today been deemed IMMINENT ENOUGH to warrant the purchase of 1.7 million “courses” of SIGA Tech’s ST-246.  Keep in mind that ST-246 is A NEW, largely untested, drug with un-known long-term side effects to humans, and is being sold to BARDA without FDA approval – thanks to Secretary Mike Leavitt’s railroading of EMERGENCY APPROVAL PROCEDURES into the FDA’s rule-book of regulations during the Pandemic Bird-Flu Hype years!

Is anybody out there in CyberSpace even the LEAST BIT CONCERNED ABOUT THIS???    Imagine, Al-Quaida agents apparently now have highly sophisticated biological weapons labs equipped with highly sophisticated computers designed to map out viral genomes.  These terrible Muslim bogeymen now have the ability to create chimera viruses by splicing DNA at exact, precise points on these sub-microscopic viruses.  Worse, they obviously now have an INCUBATION facility in order to produce these killer ORTHOPOX chimera viruses in a large enough quantity to release them in a biological attack against America!!!!

Wow!   Think about it.  1.7 million “courses” of ST-246 at around $100 USD per course?   Do the math.   Big money.   Problem, reaction, solution.   No wonder the CDC issued their warning about “Zombie Apocalypse” in May.   I submit the only ZOMBIES we should fear are the people in Washington and BARDA who are so incredibly evil they are actively creating and producing chimera rabies, influenza, and smallpox killer viruses – and then sharing documentation to outfits like SIGA so that anti-pox drugs can be produced and sold to the highest bidders.

If this doesn’t constitute a “clear and present danger” to America (and the world) – I personally don’t know what does.

A. True Ott, PhD